40.65
price up icon5.83%   2.24
after-market Dopo l'orario di chiusura: 40.10 -0.55 -1.35%
loading
Precedente Chiudi:
$38.41
Aprire:
$38.11
Volume 24 ore:
703.57K
Relative Volume:
0.48
Capitalizzazione di mercato:
$291.38M
Reddito:
-
Utile/perdita netta:
$-121.02M
Rapporto P/E:
-3.6101
EPS:
-11.26
Flusso di cassa netto:
$-114.09M
1 W Prestazione:
+2.19%
1M Prestazione:
+115.31%
6M Prestazione:
+121.53%
1 anno Prestazione:
-88.32%
Intervallo 1D:
Value
$38.06
$41.77
Intervallo di 1 settimana:
Value
$36.77
$44.30
Portata 52W:
Value
$7.31
$363.20

Tonix Pharmaceuticals Holding Corp Stock (TNXP) Company Profile

Name
Nome
Tonix Pharmaceuticals Holding Corp
Name
Telefono
212-980-9155
Name
Indirizzo
26 MAIN STREET, SUITE 101, CHATHAM, NY
Name
Dipendente
81
Name
Cinguettio
@TONIXPharma
Name
Prossima data di guadagno
2025-03-17
Name
Ultimi documenti SEC
Name
TNXP's Discussions on Twitter

Confronta TNXP con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
TNXP
Tonix Pharmaceuticals Holding Corp
40.65 291.38M 0 -121.02M -114.09M -11.26
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
450.50 113.52B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
493.22 52.93B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
300.83 39.71B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
585.93 35.00B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
255.86 26.57B 3.81B -644.79M -669.77M -6.24

Tonix Pharmaceuticals Holding Corp Stock (TNXP) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2022-04-18 Iniziato Noble Capital Markets Outperform
2019-04-18 Aggiornamento ROTH Capital Neutral → Buy
2017-08-18 Aggiornamento ROTH Capital Neutral → Buy
2016-09-07 Downgrade ROTH Capital Buy → Neutral
2016-02-17 Reiterato Oppenheimer Outperform
2015-11-04 Iniziato Cantor Fitzgerald Buy
2015-06-12 Iniziato Oppenheimer Outperform
2015-02-17 Reiterato ROTH Capital Buy
2014-09-29 Reiterato ROTH Capital Buy
Mostra tutto

Tonix Pharmaceuticals Holding Corp Borsa (TNXP) Ultime notizie

pulisher
Jun 06, 2025

Tonix Pharmaceuticals to Showcase Rheumatologic Research at EULAR 2025 - citybuzz -

Jun 06, 2025
pulisher
Jun 05, 2025

Tonix Pharmaceuticals Announces Poster Presentation at the Annua - GuruFocus

Jun 05, 2025
pulisher
Jun 05, 2025

Tonix Pharmaceuticals Announces Poster Presentation at the Annual European Congress of Rheumatology (EULAR) 2025 | TNXP Stock News - GuruFocus

Jun 05, 2025
pulisher
Jun 05, 2025

Tonix Pharmaceuticals Announces Poster Presentation at the - GlobeNewswire

Jun 05, 2025
pulisher
Jun 04, 2025

Northern Trust Corp Acquires New Shares in Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) - Defense World

Jun 04, 2025
pulisher
Jun 03, 2025

Tonix Pharmaceuticals (TNXP) Price Target Raised to $65 by Alliance Global Partners | TNXP Stock News - GuruFocus

Jun 03, 2025
pulisher
Jun 01, 2025

Wall Street Zen Downgrades Tonix Pharmaceuticals (NASDAQ:TNXP) to Sell - Defense World

Jun 01, 2025
pulisher
May 30, 2025

Tonix Pharmaceuticals: August PDUFA Date For Fibromyalgia Med A Risky Bet (NASDAQ:TNXP) - Seeking Alpha

May 30, 2025
pulisher
May 29, 2025

Tonix Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational Highlights - mx.advfn.com

May 29, 2025
pulisher
May 29, 2025

How the (TNXP) price action is used to our Advantage - news.stocktradersdaily.com

May 29, 2025
pulisher
May 29, 2025

Tonix Pharmaceuticals (TNXP) Stock Surges Over 10%: What's Fueling the Rally and What's Next? - Daily Chhattisgarh News

May 29, 2025
pulisher
May 28, 2025

What's Going On With Tonix Pharmaceuticals Stock? - Benzinga

May 28, 2025
pulisher
May 28, 2025

TNXP: Preparations Continue for Potential Commercial Launch of TNX-102 SL in Fibromyalgia… - Yahoo Finance

May 28, 2025
pulisher
May 23, 2025

Tonix Pharmaceuticals CEO Highlights Strategic Vision at Healthcare Showcase - citybuzz -

May 23, 2025
pulisher
May 22, 2025

Tonix Pharmaceuticals Announces Presentation at the A.G.P. Annual Healthcare Company Showcase - GlobeNewswire

May 22, 2025
pulisher
May 21, 2025

Tonix begins trial for stress reaction treatment By Investing.com - Investing.com South Africa

May 21, 2025
pulisher
May 21, 2025

Tonix begins trial for stress reaction treatment - Investing.com Australia

May 21, 2025
pulisher
May 21, 2025

Tonix Pharmaceuticals Announces First Patient Dosed in Phase 2 O - GuruFocus

May 21, 2025
pulisher
May 21, 2025

Tonix Pharmaceuticals (TNXP) Commences Phase 2 Trial for Stress Disorder Treatment | TNXP Stock News - GuruFocus

May 21, 2025
pulisher
May 21, 2025

Tonix Pharmaceuticals Announces First Patient Dosed In Phase 2 Oasis Study Of TNX-102 SL For Reduction Of Acute Stress Reaction - marketscreener.com

May 21, 2025
pulisher
May 21, 2025

Tonix Pharmaceuticals Announces First Patient Dosed in - GlobeNewswire

May 21, 2025
pulisher
May 21, 2025

DoD Backs Revolutionary Acute Stress Treatment: First Patient Dosed in $3M Phase 2 Trial - Stock Titan

May 21, 2025
pulisher
May 16, 2025

Tonix Pharmaceuticals (TNXP) Stock Surges Following Insider Buying And Q1 Results - Benzinga

May 16, 2025
pulisher
May 15, 2025

Stocks To Watch: Tonix Pharmaceuticals Sees RS Rating Jump To 89 - inkl

May 15, 2025
pulisher
May 14, 2025

Tonix Pharmaceuticals Recruits Seasoned Industry Atty As GC - Law360

May 14, 2025
pulisher
May 14, 2025

Tonix Pharma Stock Soars After Roping In Former Celgene Corp Executive Joseph Hand: Retail Gets More Positive - Investing.com India

May 14, 2025
pulisher
May 14, 2025

Tonix Pharmaceuticals Names Joseph Hand as General Counsel and Executive Vice President of Operations - citybuzz -

May 14, 2025
pulisher
May 14, 2025

Tonix Pharmaceuticals Appoints Joseph Hand, Esq., as General Counsel and Executive Vice President of Operations - citybiz

May 14, 2025
pulisher
May 14, 2025

Tonix Pharmaceuticals (TNXP) Appoints New General Counsel and EV - GuruFocus

May 14, 2025
pulisher
May 14, 2025

Tonix Pharmaceuticals (TNXP) Appoints New General Counsel and EVP of Operations | TNXP Stock News - GuruFocus

May 14, 2025
pulisher
May 14, 2025

Tonix Pharma Appoints New General Counsel and EVP - TipRanks

May 14, 2025
pulisher
May 14, 2025

Tonix Pharmaceuticals Announces Appointment of Joseph Hand, - GlobeNewswire

May 14, 2025
pulisher
May 14, 2025

Former Celgene $74B Deal Leader Joins Tonix as EVP Before Critical Fibromyalgia Drug Decision - Stock Titan

May 14, 2025
pulisher
May 13, 2025

Tonix Pharmaceuticals Reports First Quarter 2025 Financial Resul - GuruFocus

May 13, 2025
pulisher
May 13, 2025

Tonix Pharmaceuticals Q1 2025 Earnings: EPS Loss of $2.84 Beats - GuruFocus

May 13, 2025
pulisher
May 12, 2025

Tonix Pharmaceuticals Holding Corp reports results for the quarter ended March 31Earnings Summary - TradingView

May 12, 2025
pulisher
May 12, 2025

Tonix Pharma earnings beat by $22.84, revenue fell short of estimates - Investing.com

May 12, 2025
pulisher
May 09, 2025

Tonix Pharmaceuticals reports annual meeting results By Investing.com - Investing.com Nigeria

May 09, 2025
pulisher
May 09, 2025

Tonix Pharmaceuticals reports annual meeting results - Investing.com Australia

May 09, 2025
pulisher
May 08, 2025

Tonix showcases promising gastric cancer data at AACR Conference - Proactive financial news

May 08, 2025
pulisher
May 08, 2025

(TNXP) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com

May 08, 2025
pulisher
May 07, 2025

Tonix Pharma drops after Q4 revenue miss - MSN

May 07, 2025
pulisher
May 06, 2025

Tonix Pharmaceuticals: Looking Past FDA Approval To Challenging Commercial Opportunity - Seeking Alpha

May 06, 2025
pulisher
Apr 29, 2025

Tonix Pharmaceuticals Reveals Promising Preclinical Data for Cancer Immunotherapy TNX-1700 - citybuzz -

Apr 29, 2025
pulisher
Apr 29, 2025

Tonix Pharma Unveils Promising Cancer Treatment Data - TipRanks

Apr 29, 2025
pulisher
Apr 29, 2025

Tonix Pharmaceuticals Presented Preclinical Data on Gastric - GlobeNewswire

Apr 29, 2025
pulisher
Apr 29, 2025

Tonix Pharmaceuticals (TNXP) Showcases Promising Cancer Research at AACR 2025 | TNXP Stock News - GuruFocus

Apr 29, 2025
pulisher
Apr 29, 2025

Tonix Pharmaceuticals Presented Preclinical Data on Gastric Canc - GuruFocus

Apr 29, 2025

Tonix Pharmaceuticals Holding Corp Azioni (TNXP) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$73.62
price up icon 1.21%
$22.20
price up icon 1.79%
$20.59
price up icon 4.36%
$33.78
price up icon 0.09%
$108.49
price down icon 1.51%
biotechnology ONC
$255.86
price down icon 0.44%
Capitalizzazione:     |  Volume (24 ore):